Ticker: AGIO

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) has reported its financial results for the quarter ended June 30, 2025, reflecting both growth in revenue from its lead product, PYRUKYND®, and significant operating losses primarily driven by research and development expenses. Key Financial Highlights: ...